Enhanced humoral response in kappa-opioid receptor knockout mice

Journal of Neuroimmunology

Volumn 134, Issue 1-2, 2003, Pages 72-81

  Gavériaux Ruff, Claire ^a   Simonin, Frédéric ^a   Filliol, Dominique ^a   Kieffer, Brigitte L ^a  

^a CNRS   (France)

Author keywords

Antibodies; Opioid receptor; Spleen; Thymus; Transgenic knockout

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; ISOPROTEIN; KAPPA OPIATE RECEPTOR; KEYHOLE LIMPET HEMOCYANIN; MU OPIATE RECEPTOR;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOPHENOTYPING; KNOCKOUT GENE; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; LYMPHOCYTE PROLIFERATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; THYMOCYTE;

ANIMALS; ANTIBODY FORMATION; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; CONCANAVALIN A; IMMUNIZATION; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MICE; MICE, KNOCKOUT; NEUROIMMUNOMODULATION; RECEPTORS, OPIOID, KAPPA; SPLEEN; THYMUS GLAND;

EID: 0037221271     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(02)00419-8     Document Type: Article

References (61)

1. Akil H., Meng F., Devine D.P., Watson S.J. Molecular and neuroanatomical properties of the endogenous opioid systems: implications for the treatment of opiate addiction. Semin. Neurosci. 9:1997;70-83.
2. Alicea C., Belkowski S., Eisenstein T.K., Adler M.W., Rogers T.J. Inhibition of primary murine macrophage cytokine production in vitro following in vitro treatment with the kappa opioid agonist U50,488H. J. Neuroimmunol. 64:1996;83-90.
3. Alicea C., Belkowski S.M., Sliker J.K., Zhu J., Liu-Chen L.-Y., Eisenstein T.K., Adler M.W., Rogers T.J. Characterization of kappa-opioid receptor transcripts expressed by T cells and macrophages. J. Neuroimmunol. 91:1998;55-62.
4. Antic J., Vasiljevic T., Stanojevic S., Vujic V., Kovacevic-Jovanovic V., Djergovic D., Miljevic C., Markovic B.M., Radulovic J. Suppression of adjuvant arthritis by kappa-opioid receptor agonist: effect of route administration and strain differences. Immunopharmacology. 34:1996;105-112.
5. Belkowski S.M., Zhu J., Liu-Chen L.Y., Eisenstein T.K., Adler M., Rogers T.J. Detection of κ-opioid receptor mRNA in immature T cells. Adv. Exp. Med. Biol. 373:1995;11-16.
6. Binder W., Scott C., Walker J.S. Involvement of substance P in the anti-inflammatory effects of the peripherally selective κ-opioid asimadoline and the NK1 antagonist GR2052171. Eur. J. Neurosci. 11:1999;2065-2072.
7. Bryant H.U., Holaday J.W. Opioids in Immunologic Processes. 1993;Springer-Verlag, Berlin.
8. Bussiere J.L., Adler M.W., Rogers T.R., Eisenstein T.K. Differential effects of morphine and naltrexone on the antibody response in various mouse strains. Immunopharmacol. Immunotoxicol. 14:1992;657-673.
9. Cabot P.J., Carter L., Gaiddon C., Zhang Q., Schäfer M., Loeffler J.P., Stein C. Immune cell-derived β-endorphin. Production, release, and control of inflammatory pain in rats. J. Clin. Invest. 100:1997;142-148.
10. Cabot P.J., Carter L., Schafer M., Stein C. Methionine-enkephalin- and Dynorphin A-release from immune cells and control of inflammatory pain. Pain. 93:2001;207-212.
11. Carr D.J.J., Blalock J.E. Naloxone administration in vivo stereoselectively alters antigen-dependent and antigen-independent immune responses. Psychoneuroendocrinology. 16:1991;407-415.
12. Chao C.C., Gekker G., Hu S., Sheng W.S., Shark K.B., Bu D.-F., Archer S., Bidlack J.M., Peterson P.K. κ Opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc. Natl. Acad. Sci. U. S. A. 93:1996;8051-8056.
13. Chuang L.F., Chuang T.K., Killam F.J., Qiu Q., Wang X.R., Lin J.-J., Kung H.-F., Sheng W., Chao C., Yu L., Chuang R.Y. Expression of kappa opioid receptors in human and monkey lymphocytes. Biochem. Biophys. Res. Commun. 209:1995;1003-1010.
14. Corazziari E. Role of opioid ligands in the irritable bowel syndrome. Can. J. Gastroenterol. 13(Suppl. A):1999;71A-75A.
15. Cosgrove D., Gray D., Dierich A., Kaufman J.M.L., Benoist C., Mathis D. Mice lacking MHC class II molecules. Cell. 66:1991;1051-1066.
16. Eisenstein T.K., Hilburger M.E. Opioid modulation of immune responses: effects on phagocyte and lymphoid cell populations. J. Neuroimmunol. 83:1998;36-44.
17. Eisenstein T.K., Meissler J.J., Rogers T.J., Geller E.B., Adler M.W. Mouse strain differences in immunosuppression by opioids in vitro. J. Pharmacol. Exp. Ther. 275:1995;1484-1489.
18. El Daly E., Chefer V., Sandill S., Shippenberg T.S. Modulation of the neurotoxic effects of methamphetamine by the selective kappa-opioid receptor agonist U69593. J. Neurochem. 74:2000;1553-1562.
19. Filliol D., Ghozland S., Chluba J., Martin M., Matthes H., Simonin F., Befort K., Gavériaux-Ruff C., Dierich A., LeMeur M., Valverde O., Maldonado R., Kieffer B.L. δ- and μ-opioid receptor-deficient mice exhibit opposing alterations of emotional responses. Nat. Genet. 25:2000;195-200.
20. Gavériaux C., Peluso J., Simonin F., Laforet J., Kieffer B. Identification of κ- and δ-opioid receptor transcripts in immune cells. FEBS Lett. 369:1995;272-276.
21. Gavériaux-Ruff C., Matthes H.W.D., Peluso J., Kieffer B.L. Abolition of morphine-immunosuppression in mice lacking the μ-opioid receptor gene. Proc. Natl. Acad. Sci. U. S. A. 95:1998;6326-6330.
22. Gavériaux-Ruff C., Filliol D., Simonin F., Matthes H.W.D., Kieffer B.L. Immunosuppression by delta-opioid antagonist naltrindole: delta- and triple mu/delta/kappa-opioid receptor knockout mice reveal a nonopioid activity. J. Pharmacol. Exp. Ther. 298:2001;1193-1198.
23. Gebhart G.F. J.J. Bonica Lecture-2000: physiology, pathophysiology, and pharmacology of visceral pain. Reg. Anesth. Pain Med. 25:2000;632-638.
24. Guan L., Townsend R., Eisenstein T.K., Adler M.W., Rogers T.J. Both T cells and macrophages are targets of k-opioid-induced imunosuppression. Brain Behav. Immun. 8:1994;229-240.
25. Guan L., Eisenstein T.K., Adler M.W., Rogers T.J. Inhibition of T cell superantigen responses following treatment with the k-opioid agonist U50,488H. J. Neuroimmunol. 75:1997;163-168.
26. Guan L., Eisenstein T.K., Adler M.W., Rogers T.J. Modulation of DPK cell function by the kappa opioid agonist U50,488H. Fe Al. Drugs of Abuse, Immunomodulation and AIDS. 1998;125-136 Plenum, New York.
27. Gunji N., Nagashima M., Asano G., Yoshino S. Expression of kappa-opioid receptor mRNA in human peripheral blood lymphocytes and the relationship between its expression and the inflammatory changes in rheumatoid arthritis. Rheumatol. Int. 19:2000;95-100.
28. Hook S., Prout M., Camberis M., König M., Zimmer A., Van Heeke G., Le Gros G. Th2-dependent airway eosinophilia is regulated by preproenkephalin. J. Neuroimmunol. 107:2000;59-65.
29. Ignatowski T.A., Bidlack J.M. Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulation as assessed by flow cytometry. J. Pharmacol. Exp. Ther. 284:1998;298-306.
30. Ignatowski T.A., Bidlack J.M. Differential kappa-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation. J. Pharmacol. Exp. Ther. 290:1999;863-870.
31. Khansari D.N., Murgo A.J., Faith R.E. Effects of stress on the immune system. Immunol. Today. 11:1990;170-175.
32. Kieffer B.L. Molecular aspects of opioid receptors. Dickenson A., Besson J.M. The Pharmacology of Pain. 1997;281-303 Springer-Verlag, Berlin.
33. Kieffer B.L., Gavériaux-Ruff C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66:2002;285-306.
34. Kowalski J. Immunomodulatory action of class μ-, ∂- and k-opioid receptor agonists in mice. Neuropeptides. 32:1998;301-306.
35. Lawrence D.M.P., El-Hamouly W., Archer S., Leary J.F., Bidlack J.M. Identification of κ opioid receptors in the immune system by indirect immunofluorescence. Proc. Natl. Acad. Sci. U. S. A. 92:1995;1062.
36. LeVier D.G., McCay J.A., Stern M.L., Harris L.S., Page D., Brown R.D., Musgrove D.L., Butterworth L.F., White K.L., Munson A.E. Immunotoxicological profile of morphine sulfate in B6C3F1 female mice. Fundam. Appl. Toxicol. 22:1994;525-542.
37. Lu B., Gerard N.P., Kolakowski L.F., Bozza M., Zurakowski D., Finco O., Carroll M.C., Gerard C. Neutral endopeptidase modulation of septic choc. J. Exp. Med. 181:1995;2271-2275.
38. Machelska H., Cabot P.J., Mousa S.A., Zhang Q., Stein C. Pain control in inflammation governed by selectins. Nat. Med. 4:1998;1425-1428.
39. Machelska H., Pfluger M., Weber W., Piranvisseh-Volk M., Daubert J.D., Dehaven R., Stein C. Peripheral effects of the kappa-opioid agonist EMD 61753 on pain and inflammation in rats and humans. J. Pharmacol. Exp. Ther. 290:1999;354-361.
40. Marotti T., Gabrilovac J., Rabati S., Smejkal-Jagar L., Rocic B., Haberstock H. Met-enkephalin modulates stress-induced alterations of the immune response in mice. Pharmacol. Biochem. Behav. 54:1996;277-284.
41. Matthes H.W.D., Maldonado R., Simonin F., Valverde O., Slowe S., Kitchen I., Befort K., Dierich A., LeMeur M., Dollé P., Tzavara E., Hanoune J., Roques B.P., Kieffer B.L. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the μ-opioid receptor gene. Nature. 383:1996;819-823.
42. McCarthy L., Wetzel M., Sliker J.K., Eisenstein T.K., Rogers T.J. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 62:2001;111-123.
43. Metzger D., Feil R. Engineering the mouse genome by site-specific recombination. Curr. Opin. Biotechnol. 10:1999;470-476.
44. Ni X.C.L., Song C.Y., Wang C.H. Dynorphin A enhances mitogen-induced proliferative response and interleukin-2 production of rat splenocytes. Neuropeptides. 33:1999;137-143.
45. Ossipov M.H., Malan T.P.J., Lai J., Porreca F. Opioid pharmacology of acute and chronic pain. Dickenson A., Besson J.M. Handbook of Experimental Pharmacology. 1997;305-327 Springer Verlag, Berlin.
46. Przewlocki R. Opioid systems and stress. Herz A. Handbook of Experimental Pharmacology: Opioids II. 1993;293-324 Springer Verlag, Berlin.
47. Radulovic J., Miljevic C., Djergovic D., Vujic V., Antic J., von Horsten S., Jankovic B.D. Opioid receptor-mediated suppression of humoral immune response in vivo and in vitro: involvement of κ opioid receptors. J. Neuroimmunol. 57:1995;55-62.
48. Refojo D., Kovalovski D., Young J.I., Rubinstein M., Holsboer F., Reul J.M.H.M., Low M.J., Arzt E. Increased splenocyte proliferative response and cytokine production in β-endorphin-deficient mice. J. Neuroimmunol. 131:2002;126-134.
49. Rothman R.B., Gorelick D.A., Heishman S.J., Eichmiller P.R., Hill B.H., Norbeck J., Liberto J.G. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J. Subst. Abuse Treat. 18:2000;277-281.
50. Roy S., Barke R.A., Loh H.H. Mu-opioid receptor-knockout mice: role of mu-opioid receptor in morphine mediated immune functions. Mol. Brain Res. 61:1998;190-194.
51. Roy S., Balasubramanian S., Sumandeep S., Charboneau R., Wang J., Melnyk D., Beilman G.J., Vatassery R., Barke R.A. Morphine directs T cells toward T(H2) differentiation. Surgery. 130:2001;304-309.
52. Sacerdote P., Manfredi B., Gaspani L., Panerai A.E. The opioid antagonist naloxone induces a shift from Type 2 to Type 1 cytokine pattern in BALB/cJ mice. Blood. 95:2000;2031-2036.
53. Sharp B.M., Roy S., Bidlack J.M. Evidence for opioid receptors on cells involved in host defense and the immune system. J. Neuroimmunol. 83:1998;45-56.
54. Shippenberg T.S., Chefer V.I., Zapata A., Heidbreder C.A. Modulation of the behavioral and neurochemical effects of psychostimulants by kappa-opioid receptor systems. Ann. N.Y. Acad. Sci. 937:2001;50-73.
55. Simonin F., Valverde O., Smadja S., Slowe S., Kitchen I., Dierich A., Le Meur M., Roques B.P., Maldonado R., Kieffer B.L. Disruption of the κ-opioid receptor gene in mice enhances sensitivity to chemical visceral pain, impairs pharmacological actions of the selective κ-agonist U-50,488H and attenuates morphine withdrawal. EMBO J. 17:1998;886-897.
56. Stein C., Schäfer M., Cabot P.J., Zhang Q., Zhou Z., Gasior M. Peripheral opioid analgesia. Pain Rev. 4:1997;173-187.
57. Taub D.D., Eisenstein T.K., Geller E.B., Adler M.W., Rogers T.J. Immunomodulatory activity of μ- and κ-selective opioid agonists. Proc. Natl. Acad. Sci. U. S. A. 88:1991;360-364.
58. Van Ree J.M., Gerrits M.A., Vanderschuren L.J. Opioids, reward and addiction: an encounter of biology, psychology, and medicine. Pharmacol. Rev. 51:1999;341-396.
59. Weber R.J., Ikejiri B., Rice K.C., Pert A., Hagan A.A. Opiate receptor mediated regulation of the immune response in vivo. NIDA Res. Monogr. Ser. 76:1987;341-348.
60. Wick M.J., Minnerath S.R., Roy S., Ramakrishnan S., Loh H.H. Differential expression of opioid receptors in human lymphoid cell lines and peripheral blood lymphocytes. J. Neuroimmunol. 64:1996;29-36.
61. Zhang L., Rogers T.J. Kappa-opioid regulation of thymocyte IL-7 receptor and C-C chemokine receptor 2 expression. J. Immunol. 164:2000;5088-5093.